Quit Genius announced that it has partnered with Alight to provide smoking and vaping cessation through Alight's proprietary Alight Worklife platform. The CDC reports that nearly 70% of people want to quit smoking, but only about 8% of all people who try to quit are successful. With Quit Genius, Alight's clients can offer their employees access to the most clinically validated tobacco cessation solution in the market, with biochemically verified 52% quit rates validated in the largest randomized-controlled trial ever undertaken for a digital tobacco cessation program.

The Quit Genius program produces sustained quit rates that are between 2 and 4 times higher than those typically observed in response to usual care. The Quit Genius tobacco program includes: An engaging mobile app that delivers a personalized Cognitive Behavioral Therapy journey A dedicated care team with 1:1 access to trusted, qualified Quit Coaches A connected device that monitors carbon monoxide levels and helps members track progress Personalized tracking tools to help members monitor personal triggers, cigarettes smoked, dollars saved and health progress Nicotine replacement therapy, including access to gum and patches to assist with cravings A library of in-app content and interactive exercises Wellness and benefits platforms also have the ability to expand the Quit Genius offering into alcohol and opioid solutions for future benefits. Quit Genius delivers the industry's most complete virtual clinical care model for addiction and recently expanded its partnership with Express Scripts to include access to the Quit Genius Alcohol and Opioid Addiction Treatment Solutions.

The Quit Genius program combines virtual behavioral therapy with approved medication and connected devices to help people overcome addiction from the comfort and privacy of their own home.